Sign up
Pharma Capital

Silence Therapeutics 'in a hot space with few competitors'

Silence Therapeutics' (LON:SLN) executive chair Annalisa Jenkins sat down with Proactive's Andrew Scott to discuss her strategy for taking the drug developer forward and the 'exciting opportunities' in the RNAi space.

On what attracted Jenkins to join Silence, she says: ''The opportunity to be at a good company with a great platform, based in Europe and in a space that I think is at a really disruptive moment in time in terms of doing great things for patients''.

 

View full SLN profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.